Article - 29/07/2009 Protein crystallisation: an attractive alternative to protein purification The production of pure crystals is a method that is normally used for the determination of the spatial structure of a protein using X-ray defraction. Crystalline proteins have a very regular structure, meaning that contaminations can to a large extent be excluded. Therefore, protein crystals only contain a small number of foreign substances, which makes them a lot more stable in solution than proteins are. Due to the aforementioned properties,…https://www.gesundheitsindustrie-bw.de/en/article/news/protein-crystallisation-an-attractive-alternative-to-protein-purification
Press release - 09/07/2009 Marcus Groettrup: Discovery in the kingdom of cells Prof. Marcus Groettrup has been closely investigating the daily defence battle of the human immune system for a number of years. The researcher from Constance has now found a substance that has the potential to revolutionise the treatment of rheumatism.https://www.gesundheitsindustrie-bw.de/en/article/press-release/marcus-groettrup-discovery-in-the-kingdom-of-cells
Article - 08/09/2014 Thomas Boehm – pushing back the frontiers of knowledge The comparison of different animal species enables us to understand the crucial principle of immune defence on condition that the right investigative approach is chosen. Prof. Dr. Thomas Boehm director of the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been doing just this for many years. Based on insights into fundamental immune system functions Boehms research is aimed at developing new strategies for the diagnosis…https://www.gesundheitsindustrie-bw.de/en/article/news/thomas-boehm-pushing-back-the-frontiers-of-knowledge
Press release - 25/02/2008 "Clinical Trials" junior researcher academy Young medical professionals or young scientists are eligible to apply for funding.https://www.gesundheitsindustrie-bw.de/en/article/press-release/clinical-trials-junior-researcher-academy
Article - 23/08/2010 Antibiotics for the prevention of malaria Researchers from Heidelberg and Berlin have shown that if malaria-infected mice are administered an antibiotic, no parasites appear in the blood and the mice are protected from this life-threatening disease. The scientists believe that antibiotics also have the potential to strengthen the human immune system as well as making it possible to provide a natural needle-free vaccination against malaria.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotics-for-the-prevention-of-malaria
Article - 15/03/2010 Campaign to eradicate malaria After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.https://www.gesundheitsindustrie-bw.de/en/article/news/campaign-to-eradicate-malaria
Article - 10/05/2008 Straight questions and answers The 14th Biotech Finance Forum offered selected biotechnology and medical technology companies from all over Europe the opportunity of an exclusive meeting with internationally operative investors from the venture capital VC scene. https://www.gesundheitsindustrie-bw.de/en/article/news/straight-questions-and-answers
Article - 11/02/2010 New interfaculty institute combines excellent basic research with clinical application Infection research is one of the major scientific beacons of the University of Tübingen, where the close thematic collaboration between scientists and doctors is the key to success. The close collaboration between scientists and doctors at the university also played a key role in the setting up of two collaborative research centres (SFB). With the recent establishment of the Interfaculty Institute for Microbiology and Infection Medicine (IMIT),…https://www.gesundheitsindustrie-bw.de/en/article/news/new-interfaculty-institute-combines-excellent-basic-research-with-clinical-application
Article - 01/12/2014 Stem cell research for preventing radiation-induced developmental damage Although ionizing radiation is known to cause cell damage and genetic modifications, its effects on embryonic development are still poorly understood. This is why Prof. Dr. Suzanne Kadereit from the Albstadt-Sigmaringen University of Applied Sciences is involved in a cooperative project that uses human embryonic stem cells for studying the effects of ionizing radiation on prenatal brain development. She heads up the only university of applied…https://www.gesundheitsindustrie-bw.de/en/article/news/stem-cell-research-for-preventing-radiation-induced-developmental-damage
Article - 22/08/2016 Ad-O-Lytics – a new biotech start-up from Ulm A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
Press release - 03/10/2011 Astonishing discovery: iron-overloading of macrophages is the cause of venous leg ulcers Around three to five per cent of people in industrial nations suffer from chronic venous leg ulcers. Elderly people are particularly prone to developing these chronic wounds. A dermatologist from Ulm has now discovered the reason why chronic venous leg ulcers fail to heal even after months or years. The scientific community is astonished by the new findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/astonishing-discovery-iron-overloading-of-macrophages-is-the-cause-of-venous-leg-ulcers
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Article - 02/05/2011 Production of high-density peptide arrays Frank Breitling and Alexander Nesterov-Müller from the Karlsruhe Institute of Technology KIT are working on the development of a second-generation peptide laser printer and a peptide chip printer based on computer chips. This development will enable the low-cost production of high-density peptide arrays consisting of up to one million peptides as well as opening up completely new areas of application.https://www.gesundheitsindustrie-bw.de/en/article/news/production-of-high-density-peptide-arrays
Press release - 10/11/2008 Trachea replacement made from pig intestines In principle human tracheas and porcine small intestines do not have much in common. However both have a tube-like structure. This was the basis for Dr. Thorsten Walles extraordinary idea. In collaboration with Professor Dr. Heike Mertsching he is working on the development of methods for turning the intestines into bioartificial trachea substitutes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/trachea-replacement-made-from-pig-intestines
Article - 29/11/2013 QIAGEN Lake Constance: a “disk player” for rapid diagnoses The diagnosis of infectious diseases frequently not only depends on the reliable identification of the pathogenic species that has caused them, but also on obtaining rapid results in order to immediately initiate appropriate therapy or further diagnostic measures. Tests are normally carried out in central laboratories, samples need to be sent to the laboratories and the results are rarely immediate. As part of the BMBF-funded project “ResCheck”,…https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-a-disk-player-for-rapid-diagnoses
Press release - 24/11/2009 Three new collaborative research centres in Baden-Württemberg The German Research Foundation (DFG) is set to establish 17 new collaborative research centres (SFBs) on 1st January 2010. Ten of the new SFBs will focus on life science research projects, and will initially be funded for a period of four years with a total of 78 million euros in funding. One of the SFBs will be established at the University of Freiburg. Six of the 17 new SFBs are SFB/Transregio projects involving researchers from several German…https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-collaborative-research-centres-in-baden-wuerttemberg
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Article - 29/07/2011 Labor Dr. Merk und Kollegen - Viruses under control It is difficult to imagine how Ochsenhausen-based Labor Dr. Merk und Kollegen (LMK) would be able to develop, produce and test medical products for bacterial and viral contaminations without using cell cultures. The medium-sized company also produces viruses for testing and has stored more than 80 different viruses – enveloped and non-enveloped ones, animal and human pathogens – at -80˚C.https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-und-kollegen-viruses-under-control
Press release - 15/11/2011 Lung cancer: CureVac presents results of a Phase I/IIa trial with an mRNA based vaccine CureVac GmbH, the mRNA vaccine company, presented at the 26th Annual SITC Meeting in Washington the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-cancer-curevac-presents-results-of-a-phase-i-iia-trial-with-an-mrna-based-vaccine
Article - 28/11/2009 "You cannot afford to fail twice in Germany" Prof. Dr. Bodo Liedvogel and Dr. Heinz Haubruck founded the company DIARECT AG in Freiburg in 1998. They not only brought 20 years of experience in industry to the company but also their entire savings. In the following interview Dr. Heinz Haubruck tells Christoph Bächtle about the return investors expect from companies how to win over potential clients and the risks associated with setting up ones own business.https://www.gesundheitsindustrie-bw.de/en/article/news/you-cannot-afford-to-fail-twice-in-germany
Article - 21/03/2011 Immunotherapy: the rocky road to clinical application Hans-Georg Rammensee has one major goal: he wants to contribute to the successful application of immunotherapy in clinical settings and is convinced that this will only be possible once individualised immunotherapies are used. Individualised immunotherapy refers to the induction of a specific immune response against specific tumour-associated antigens. Rammensee has made major progress in this area and is now focused on overcoming the obstacles…https://www.gesundheitsindustrie-bw.de/en/article/news/immunotherapy-the-rocky-road-to-clinical-application
Article - 24/03/2014 Vaccine against papillomaviruses protects from skin cancer Papillomaviruses are thought to cause non-melanoma skin cancer in people exposed to UV radiation, especially those who have suppressed immune systems. Researchers from the German Cancer Research Center (DKFZ) and the Charité University Hospital in Berlin have developed a vaccine that protects mice against such skin tumours. The vaccine is even effective in mice that have previously been infected with papillomaviruses and that have suppressed…https://www.gesundheitsindustrie-bw.de/en/article/news/vaccine-against-papillomaviruses-protects-from-skin-cancer
Dossier - 12/12/2011 Development of new molecular biomarkers Biomarkers are playing an increasing role in drug discovery and development. They can be used as molecular indicators for diseases and disease risks as well as for monitoring the effectiveness of therapy. Highly specific molecular biomarkers are being identified using state-of-the-art technologies from the fields of genomics, proteomics and metabolomics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/development-of-new-molecular-biomarkers
Article - 12/03/2009 Chronic inflammatory intestinal diseases – the search for greater tolerance Intestinal flora plays a key role in the development of Crohns disease or ulcerative colitis. Dr. Julia-Stefanie Frick a microbiologist from Tübingen is investigating why some of these usually harmless bacteria suddenly lead to severe inflammation. Her research which has recently been awarded a research prize might now pave the way to preventive therapy.https://www.gesundheitsindustrie-bw.de/en/article/news/chronic-inflammatory-intestinal-diseases-the-search-for-greater-tolerance
Article - 29/11/2010 Against chronic liver inflammation and liver cancer Chronic hepatitis B and C are the major causes of liver cancer. In contrast to hepatitis B viruses, there is no hepatitis C virus vaccination available. New research carried out by Professor Bartenschlager and his colleagues from Heidelberg might give rise to new strategies for the development of vaccines and medications for the prevention and treatment of chronic hepatitis C virus infections.https://www.gesundheitsindustrie-bw.de/en/article/news/against-chronic-liver-inflammation-and-liver-cancer